Physician profile
Kathryn D Watts
NPI 1790098853
$5,346.94
in general payments reported to CMS, 2019-2025
29 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 97% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $486 · 2022: $768 · 2023: $1,153 · 2024: $1,491 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,058 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,057.96 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $843.28 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $561.16 | 2021-2025 | |
| Astellas Pharma US INC | $556.27 | 2021-2025 | Myrbetriq, Xtandi |
| Dendreon Pharmaceuticals LLC | $549.54 | 2021-2025 | Provenge |
| Pfizer INC. | $452.49 | 2021-2025 | |
| Janssen Biotech, INC. | $357.89 | 2023-2024 | Erleada, Akeega, Balversa |
| Ferring Pharmaceuticals INC. | $304.98 | 2024-2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $170.20 | 2023-2025 | Pylarify |
| Endo Pharmaceuticals INC. | $145.47 | 2021-2024 | Aveed, Xiaflex |
| Myovant Sciences INC. | $142.59 | 2021-2022 | |
| Axonics, INC. | $123.53 | 2022-2024 | Axonics |
| Blue Earth Diagnostics | $122.84 | 2023-2025 | Posluma |
| Tolmar Pharmaceuticals, INC. | $122.02 | 2021-2022 | |
| Accord Healthcare, INC. | $109.90 | 2023-2024 | |
| Urovant Sciences INC | $109.82 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $102.26 | 2021-2025 | Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $82.20 | 2022-2025 | Keytruda, Keytruda Qlex |
| Endo USA, INC. | $71.87 | 2024-2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $71.00 | 2025 | |
| Abbvie INC. | $66.06 | 2024-2025 | |
| Tolmar, INC. | $57.65 | 2023 | |
| Innovation Technologies INC | $48.46 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $45.00 | 2024-2025 | |
| Tempus Ai, INC | $29.65 | 2024 | |
| Novartis Pharmaceuticals Corporation | $27.91 | 2024 | |
| Immunitybio, INC. | $20.99 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.22 | 2025 | Givlaari |
| Sun Pharmaceutical Industries INC. | $17.34 | 2024 | |
| Olympus America INC. | $16.35 | 2023 | Itind System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.